Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5GZO

Structure of neutralizing antibody bound to Zika envelope protein

Summary for 5GZO
Entry DOI10.2210/pdb5gzo/pdb
Related5GZN
DescriptorGenome polyprotein, Antibody heavy chain, Antibody light chain (3 entities in total)
Functional Keywordszika virus, human neutralizing antibodies, envelope protein, molecular determinants, viral protein-immune system complex, viral protein/immune system
Biological sourceZika virus (ZIKV)
More
Cellular locationVirion membrane ; Multi-pass membrane protein : H9A910
Total number of polymer chains6
Total formula weight182761.19
Authors
Primary citationWang, Q.,Yang, H.,Liu, X.,Dai, L.,Ma, T.,Qi, J.,Wong, G.,Peng, R.,Liu, S.,Li, J.,Li, S.,Song, J.,Liu, J.,He, J.,Yuan, H.,Xiong, Y.,Liao, Y.,Li, J.,Yang, J.,Tong, Z.,Griffin, B.D.,Bi, Y.,Liang, M.,Xu, X.,Qin, C.,Cheng, G.,Zhang, X.,Wang, P.,Qiu, X.,Kobinger, G.,Shi, Y.,Yan, J.,Gao, G.F.
Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus
Sci Transl Med, 8:369ra179-369ra179, 2016
Cited by
PubMed Abstract: The 2015-2016 outbreak of Zika virus (ZIKV) disease has affected many countries and is a major public health concern. ZIKV is associated with fetal microcephaly and neurological complications, and countermeasures are needed to treat and prevent ZIKV infection. We report the isolation of 13 specific human monoclonal antibodies from a single patient infected with ZIKV. Two of the isolated antibodies (Z23 and Z3L1) demonstrated potent ZIKV-specific neutralization in vitro without binding or neutralizing activity against strains 1 to 4 of dengue virus, the closest relative to ZIKV. These two antibodies provided postexposure protection to mice in vivo. Structural studies revealed that Z23 and Z3L1 bound to tertiary epitopes in envelope protein domain I, II, or III, indicating potential targets for ZIKV-specific therapy. Our results suggest the potential of antibody-based therapeutics and provide a structure-based rationale for the design of future ZIKV-specific vaccines.
PubMed: 27974667
DOI: 10.1126/scitranslmed.aai8336
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.755 Å)
Structure validation

226707

数据于2024-10-30公开中

PDB statisticsPDBj update infoContact PDBjnumon